Wird geladen...
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15–60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will benefit fro...
Gespeichert in:
| Veröffentlicht in: | J Immunother Cancer |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6858629/ https://ncbi.nlm.nih.gov/pubmed/31730012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0805-8 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|